A citation-based method for searching scientific literature

Raymond R Townsend, Israel Machin, Jimmy Ren, Angelina Trujillo, Masato Kawaguchi, Ujjwala Vijapurkar, Chandrasekharrao V Damaraju, Michael Pfeifer. J Clin Hypertens (Greenwich) 2016
Times Cited: 55







List of shared articles



Times cited

Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
C Berra, R Manfrini, D Regazzoli, M G Radaelli, O Disoteo, C Sommese, P Fiorina, G Ambrosio, F Folli. Pharmacol Res 2020
3

An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.
Lakshini Y Herat, Vance B Matthews, Aaron L Magno, Marcio G Kiuchi, Revathy Carnagarin, Markus P Schlaich. Expert Opin Pharmacother 2020
2


Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension.
Elias A Sanidas, Dimitrios P Papadopoulos, Erifili Hatziagelaki, Charalampos Grassos, Maria Velliou, John Barbetseas. Am J Hypertens 2020
6

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang,[...]. Circulation 2021
2


Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
Charalampos I Liakos, Dimitrios P Papadopoulos, Elias A Sanidas, Maria I Markou, Erifili E Hatziagelaki, Charalampos A Grassos, Maria L Velliou, John D Barbetseas. Am J Cardiovasc Drugs 2021
0

Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Keith C Ferdinand, Joseph L Izzo, Jisoo Lee, Leslie Meng, Jyothis George, Afshin Salsali, Leo Seman. Circulation 2019
30

The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros. Expert Rev Clin Pharmacol 2017
7

Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure.
Konstantinos Imprialos, Konstantinos Stavropoulos, Vasilios Papademetriou. Heart Fail Clin 2019
0


Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
0